## IQV: IQVIA Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($211.65)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Stifel raises IQVIA Holdings stock price target to $273 on recovery outlook**
- Source: Investing.com UK | 20251217T193355 | Bullish | Relevance: 97%
- Stifel has increased its price target for IQVIA Holdings (NYSE:IQV) stock to $273.00 from $254.00, maintaining a Buy rating based on an anticipated industry recovery extending into 2026. This adjustment follows investor meetings yielding insights into the company's strong market positioning and expected medium-term revenue growth of 6%-9%. The company has also recently undertaken strategic initiatives, including an amended credit agreement and a collaboration with Amazon Web Services.

**2. Stifel raises IQVIA Holdings stock price target to $273 on recovery outlook**
- Source: Investing.com Canada | 20251217T200922 | Bullish | Relevance: 96%
- Stifel has increased its price target for IQVIA Holdings (NYSE:IQV) stock to $273.00 from $254.00, maintaining a Buy rating based on insights from recent investor meetings and the industry's recovery trajectory extending into 2026. The firm expressed confidence in IQVIA's market positioning as a "best-in-class player" and expects the company to return to medium-term revenue growth of 6%-9%. This adjusted target suggests significant upside from the current price, with the stock trading near its 52-week high.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 1 ($5.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Insider selling cluster: $5.8M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($5.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $37.9B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 17.2 |
| Current P/E | 18.7 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 1.9pp (needs >3.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.22x) but short-term weakness (below SMA20). MACD histogram bearish (-1.01), momentum weakening. RSI neutral at 51. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.12% (CS: 52) | Neutral |
| RSI_14 | 51.4 | Neutral |
| MACD Histogram | -1.01 | Bearish |
| vs SMA20 | 0.989x | Below |
| vs SMA50 | 1.020x | Above |
| vs SMA200 | 1.222x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $222.47
- **Stop Loss:** $211.65 (4.9% risk)
- **Target:** $233.29 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 87
- **Position Value:** $19,354.89
- **Portfolio %:** 19.35%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*